REPL Stock Price - Replimune Group, Inc. logo

REPL Stock Price

Replimune Group, Inc.

$19.69
-$1.72(-8.03%)
48
Overall
60
Value
75
Tech
10
Quality
How is this score calculated?
Market Cap
$1.87B
Volume
2.43M
52W Range
$1.50 - $23.54
Target Price
$23.33

REPL stock price is $19.69 (-8.03% on the day), giving Replimune Group, Inc. a market cap of $1.87B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.

REPL Stock Overview

Price
$19.69
Previous close
$21.41
Open
$21.36
Market cap
$1.87B
52-week range
$1.50 - $23.54
1-year price target
$23.33
Sector
Healthcare
Industry
Biotechnology
Exchange
Nasdaq
MarketXLS Rank
48

About Replimune Group, Inc.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

ABCD
1SymbolPriceChangeVol
2REPL$19.69-8.0%2.43M
3
4
5
6

Get Replimune Group, Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.